Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Immune Tolerance Mechanisms and Autoimmune Outcomes: Full Evidence Review

Previous related pageWhy Vitamin D Autoimmune Findings Differ: Full Evidence ReviewNext related pageLocal Vitamin D Metabolism and Autoimmune Tissues: Full Evidence Review
Study at a glance

What was studied?

This review compares eight underlying studies of immune restraint and autoimmune outcomes. Autoimmunity means responses against the body’s own material. Some studies exposed human cells to active vitamin D hormone in the laboratory. Others assigned people by chance to vitamin D3 or an inactive comparison.

What was found?

Active vitamin D hormone supported some restraining functions in cultured cells. One human trial did not clearly increase the share of blood cells identified as natural regulatory T cells, which help restrain responses. Updated VITAL results left uncertainty about fewer autoimmune diagnoses. PREVANZ found no clear difference on a combined outcome of new clinical episodes or scan changes. D-Lay MS improved a combined outcome mainly involving scans, without clear improvement in clinical episodes alone or disability.

What does it mean?

Measured cell proteins, short tests of whether cells restrain other cells and autoimmune diagnoses are different outcomes. The clinical trials did not show that the laboratory mechanisms caused their results.

What are the limits?

Later VITAL follow-up watched participants after assigned supplements stopped. It was not another treatment period assigned by chance. Early neurological disease differs from prevention in healthy people. No personal dose or blood target for tolerance was established.

Read the full article below ↓

Vitamin D signalling can support tolerance-related functions in experimental immune cells, but clinical prevention of autoimmunity is a separate question. Dendritic-cell conditioning and regulatory T-cell responses provide plausible mechanisms. Human intervention results are mixed, and updated autoimmune-trial findings are less decisive than the original VITAL headline. This review connects mechanism to outcomes while keeping that unproved causal link visible. Read the shorter counterpart, Vitamin D, Immune Tolerance Mechanisms and Autoimmune Outcomes: Study Summary.

What counts as evidence of immune tolerance?

Tolerance means limiting inappropriate immune responses, including responses to the body’s own material. Regulatory T cells and dendritic cells can contribute, but a favourable marker is not equivalent to durable self-tolerance. A functional suppression assay supplies more information than a marker, while a lower disease incidence supplies a different kind of evidence again. Vitamin D and Immune Tolerance introduces the physiology; this review examines those evidential steps.

Eight underlying studies are assessed: two conditional human T-cell experiments, two dendritic-cell metabolic studies, a randomized circulating-regulatory-cell trial, VITAL autoimmune outcomes and two early demyelinating-disease trials. The original and updated VITAL publications are one underlying trial. Shared investigators among several laboratory papers also limit claims of independent external replication. [1] [2] [3] [4] [5] [6] [9] [7] [8]

No selected clinical trial demonstrates that its outcome was mediated by the T-cell or dendritic mechanisms described below. Mechanistic plausibility and clinical effects cannot establish mediation merely by appearing in the same review. The prevention question also differs between initially healthy older adults and people who already have a clinically isolated neurological syndrome.

Regulatory T-cell characteristics were conditional

Jeffery and colleagues’ 2009 experiments used activated healthy-donor CD4 T cells. Calcitriol, the active vitamin D hormone, reduced interferon-gamma, interleukin-17 and interleukin-21, and increased interleukin-10 and CTLA-4 under the tested conditions. These signalling proteins and the CTLA-4 checkpoint do not all measure the same function. Interleukin-2 was important for FoxP3 induction and the functional regulatory response. FoxP3 is a protein associated with regulatory T cells, but its expression alone does not establish a stable lineage. [1]

Cells grown with calcitriol and interleukin-2 suppressed the proliferation of fresh responder T cells in a short laboratory assay. The comparison therefore tested an effect on another cell population, beyond identifying FoxP3 or CTLA-4 on the conditioned cells. This supports an actual regulatory function under the tested conditions. However, markers were not indefinitely maintained after one stimulation. Small donor sets, artificial activation and direct active-hormone exposure prevent a conclusion that ordinary supplements permanently convert effector cells into self-tolerant cells.

The 2012 study added the local-metabolism question. Dendritic cells helped make the circulating precursor 25-hydroxyvitamin D3 available as active hormone. Direct calcitriol bypassed the conversion step. In contrast, precursor responses were stronger with dendritic-cell support than with bead-only T-cell activation in this system. Dendritic-cell maturation and contact with activated T cells increased converting-enzyme expression, while binding protein restricted precursor availability and the downstream response. These controls support a conditional local mechanism rather than simply an association between two markers. FoxP3 cultures also received transforming growth factor-beta and interleukin-2, so the result cannot be attributed to vitamin D acting alone. [2]

The relationship to Vitamin D and Adaptive Immunity is clear, but the tolerance-specific contribution is narrower: cellular access and accompanying signals qualify the mechanism. This review does not infer a serum threshold, a binding-protein genetic test or an absolute conversion yield from these experiments. The distinction between precursor and active hormone also prevents direct translation from culture concentration to oral dose.

The checkpoint described in Vitamin D, CTLA-4 and Immune Restraint: Full Study explains a related mechanism for limiting the activating signals available to other T cells. This is functional restraint, which is different from proof of antigen-specific self-tolerance. Regulatory mechanisms can participate in restraint without establishing that they prevented a patient’s disease.

Dendritic conditioning involved active metabolism

Dendritic cells display material to T cells and provide signals that influence activation. A cell described as tolerogenic is less likely to stimulate certain responses under specified conditions. That description requires attention to function, not an assumption that every such cell is metabolically inactive. Ferreira and colleagues directly addressed the metabolic part in human donor-derived cells. [3]

The researchers conditioned developing dendritic cells with calcitriol, matured them with inflammatory stimuli and tested their ability to stimulate T cells. Conditioned cells showed reduced stimulatory function alongside increased selected glycolytic and oxidative measurements. Restricting glucose availability or interfering with metabolic and PI3K/mTOR-related pathways impaired parts of the conditioned phenotype and partly restored T-cell stimulation.

These interventions support participation of metabolic pathways. They do not establish one exclusive causal sequence. Inhibitors can affect survival and more than one pathway; simultaneous changes in phenotype and metabolism do not prove every proposed arrow in a model. Hypoxia also changed aspects of the phenotype without abolishing functional restraint. The supported interpretation is metabolic involvement in this culture system, rather than tolerance resulting from a uniform reduction of cellular energy use. [3]

Garcia and colleagues examined fatty-acid synthesis during calcitriol conditioning of human monocyte-derived dendritic cells. They measured respiration, carbon incorporation and effects of a fatty-acid-synthase inhibitor. Calcitriol altered aspects of metabolic use and phenotype, with responses depending on maturation conditions. The inhibitor reduced interleukin-10 and CD14 but did not appreciably change every antigen-presentation or costimulatory marker measured. [4]

Crucially, that study did not directly test T-cell suppression or regulatory-T-cell generation. It extends the metabolic mechanism at the phenotype level; it cannot be cited as a second direct functional tolerance demonstration. Carbon incorporation into fatty acids is also not identical to an increase in every lipid pool. Small donor sets, multiple comparisons and pharmacological specificity remain important limits.

Both dendritic studies used healthy-donor cells, but their different endpoints support different levels of functional inference. Their relevance to Vitamin D and Immune Modulation is conditional regulation of activation. Neither experiment shows that supplements prevent autoimmunity, nor that all dendritic cells become regulatory under every activation history.

A randomized human trial did not show natural-Treg expansion

D-SIRe2 provides a human counterweight to extrapolating regulatory-cell culture findings. Sixty-two healthy adults were randomized to 400 international units of vitamin D3 daily or placebo for forty-three weeks. The study measured circulating natural regulatory T-cell frequency and stimulated laboratory responses across seasons. The baseline sample set was smaller than the randomized population; follow-up denominators also varied. [5]

Vitamin D status increased, but there was no clear treatment effect on natural-Treg frequency, stimulated proliferation or interleukin-10. A seasonal change in stimulated interferon-gamma was attenuated. That is a conditional laboratory observation, not demonstrated autoimmune protection. The study did not test Treg suppressive function or clinical disease incidence.

The result does not establish that vitamin D can never influence tolerance. It concerns one low-dose regimen in a small healthy population. It nevertheless refutes the assumption that cultured regulatory-marker induction guarantees expansion of circulating natural Tregs after supplementation. Tissue function, cell frequency and induced versus naturally occurring regulatory populations must remain separate. [5]

VITAL: the current evidence includes the updated result

VITAL randomized 25,871 older US adults in a factorial vitamin D and marine omega-3 trial. Vitamin D3 at 2,000 international units daily was compared with placebo over a median 5.3 years. Participants were not selected for deficiency. New autoimmune diagnoses were reported and checked against medical records. This was a clinical incidence question, not a trial of cell-culture tolerance mechanisms. [6]

The original 2022 report found 123 versus 155 confirmed autoimmune cases, with a hazard ratio of 0.78 and a 95% confidence interval from 0.61 to 0.99. That result generated a widely repeated 22% relative-reduction headline. A hazard ratio is a relative event-rate measure over follow-up, not an absolute percentage-point reduction in the number of people affected.

The 2024 report added ascertainment and follow-up. Its updated randomized-period result was 173 versus 203 cases, hazard ratio 0.85, with a confidence interval from 0.70 to 1.04. The interval includes no difference. The combined randomized and two-year posttrial result was 255 versus 259 cases, hazard ratio 0.98, from 0.83 to 1.17. The updated evidence therefore does not sustain the original headline as a settled current estimate. [9]

The posttrial period was observational after study supplementation ended. It must not be described as seven years of continuous randomized treatment. Outside supplement use, willing-participant follow-up and later ascertainment affect interpretation. The outcome also combines heterogeneous autoimmune diseases with relatively few events for individual diagnoses.

The original and updated reports are not independent replications. Nor does either establish Treg or dendritic-cell mediation. The defensible interpretation uses the reported principal estimates and preserves their uncertainty. Research doses in these studies are methods, not a personal prevention regimen.

Early demyelinating disease: a null trial and a positive composite

PREVANZ studied people after a clinically isolated syndrome with abnormal imaging, rather than preventing the first autoimmune event in a healthy population. Its modified intention-to-treat analysis included 199 participants. Daily placebo or vitamin D3 at 1,000, 5,000 or 10,000 international units was compared over forty-eight weeks. Baseline vitamin D status was generally adequate. [7]

No dose clearly reduced the primary relapse-or-imaging disease-activity outcome. The unadjusted hazard ratios were 0.87, 1.37 and 1.28, respectively, with wide confidence intervals crossing one. The trial recruited fewer participants than planned and included few with severe deficiency. These limits prevent a universal conclusion of no effect, but the null comparisons must remain part of the evidence.

D-Lay MS used a different regimen and population. Of 316 randomized participants with a recent clinically isolated syndrome, 303 took at least one dose and entered the principal analysis. Vitamin D3 at 100,000 international units every two weeks was compared with placebo over up to twenty-four months. This high research exposure is not treatment guidance or a substitute for established care. [8]

The primary relapse-or-MRI-activity composite occurred in 94 of 156 vitamin D recipients and 109 of 147 placebo recipients. The hazard ratio was 0.66, with a 95% confidence interval from 0.50 to 0.87. This reported estimate comes from the model adjusted for centre and baseline contrast-enhancing lesions on the diagnostic scan. MRI means magnetic resonance imaging. The composite’s positive result was driven largely by imaging; relapse alone had a hazard ratio of 0.69, from 0.42 to 1.16, and clinical disability did not clearly improve.

It would therefore be inaccurate to say the trial reduced relapses or disability by 34%. It did not show prevention of multiple sclerosis in healthy people. Many participants already met contemporary early-disease criteria. Local image interpretation, scheduled scans, the modified analysis and exploratory secondary comparisons further qualify the result. [8]

Differences between PREVANZ and D-Lay MS include baseline state, regimen, duration, population and outcome timing. They can generate hypotheses about why results differed. They do not prove that intermittent dosing is superior to daily dosing: there was no head-to-head randomized comparison. Neither trial established tolerance-cell mediation, and dose arms or subgroup analyses are not additional independent studies.

What can be connected, and what remains unproved?

Evidential stepWhat the selected studies addWhat remains unresolved
Regulatory T-cell conditioningConditional markers and short functional restraintStable antigen-specific self-tolerance
Dendritic-cell metabolismFunctional restraint in one study and phenotype/metabolic changes in anotherOne exclusive causal pathway or clinical prevention
Circulating natural TregsNo clear frequency increase in D-SIRe2Every tissue function and regimen
Incident autoimmune diseaseOriginal and updated VITAL estimatesA settled preventive effect or tolerance mediation
Early demyelinating diseasePREVANZ null; D-Lay positive imaging-dominated compositeGeneral primary prevention, relapse or disability benefit

The relationship to Vitamin D and Autoimmune Mechanisms is mechanistic plausibility with clinical limits. Vitamin D and Immune Overactivation concerns inappropriate response magnitude, which overlaps tolerance but is not identical to self-antigen discrimination. Vitamin D and Cytokine Balance concerns signalling balance, while Local Activation of Vitamin D in Non-Classical Target Tissues: Full Study explains local activation, which helps distinguish precursor supply from exposure to active hormone. None of these physiological relationships supplies a clinical endpoint missing from a study.

Overall, the laboratory evidence supports conditional tolerance-related regulation. Human supplementation does not simply reproduce every cultured phenotype, and clinical outcomes remain population: and endpoint-specific. Updated VITAL findings, the natural-Treg null result and the disagreement between early-disease trials all limit a universal prevention claim. The combined evidence does not establish a personal dose, a serum target for tolerance or proof that Treg and dendritic mechanisms caused a clinical benefit.

Primary sources

[1] Jeffery LE et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. Journal of immunology (Baltimore, Md. : 1950). 2009;183(9):5458-5467. DOI: 10.4049/jimmunol.0803217. PMID: 19843932.

[2] Jeffery LE et al. Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. Journal of immunology (Baltimore, Md. : 1950). 2012;189(11):5155-5164. DOI: 10.4049/jimmunol.1200786. PMID: 23087405.

[3] Ferreira GB et al. Vitamin D3 Induces Tolerance in Human Dendritic Cells by Activation of Intracellular Metabolic Pathways. Cell reports. 2015;10(5):711-725. DOI: 10.1016/j.celrep.2015.01.013. PMID: 25660022.

[4] Garcia AM et al. Tolerogenic effects of 1,25-dihydroxyvitamin D on dendritic cells involve induction of fatty acid synthesis. The Journal of steroid biochemistry and molecular biology. 2021;211:105891. DOI: 10.1016/j.jsbmb.2021.105891. PMID: 33785437.

[5] Maboshe W et al. Low-Dose Vitamin D3 Supplementation Does Not Affect Natural Regulatory T Cell Population but Attenuates Seasonal Changes in T Cell-Produced IFN-γ: Results From the D-SIRe2 Randomized Controlled Trial. Frontiers in immunology. 2021;12:623087. DOI: 10.3389/fimmu.2021.623087. PMID: 34262557.

[6] Hahn J et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ (Clinical research ed.). 2022;376:e066452. DOI: 10.1136/bmj-2021-066452. PMID: 35082139.

[7] Butzkueven H et al. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain : a journal of neurology. 2024;147(4):1206-1215. DOI: 10.1093/brain/awad409. PMID: 38085047.

[8] Thouvenot E et al. High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial. JAMA. 2025;333(16):1413-1422. DOI: 10.1001/jama.2025.1604. PMID: 40063041.

[9] Costenbader KH et al. Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.). 2024;76(6):973-983. DOI: 10.1002/art.42811. PMID: 38272846.

Related reading

Original sources

Source

1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3

Published in Journal of immunology (Baltimore, Md. : 1950) (2009).

Publication details

[1] Jeffery LE et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. Journal of immunology (Baltimore, Md. : 1950). 2009;183(9):5458-5467. DOI: 10.4049/jimmunol.0803217. PMID: 19843932.

Read more →
Source

Low-Dose Vitamin D3 Supplementation Does Not Affect Natural Regulatory T Cell Population but Attenuates Seasonal Changes in T Cell-Produced IFN-γ: Results From the D-SIRe2 Randomized Controlled Trial

Published in Frontiers in immunology (2021).

Publication details

[5] Maboshe W et al. Low-Dose Vitamin D3 Supplementation Does Not Affect Natural Regulatory T Cell Population but Attenuates Seasonal Changes in T Cell-Produced IFN-γ: Results From the D-SIRe2 Randomized Controlled Trial. Frontiers in immunology. 2021;12:623087. DOI: 10.3389/fimmu.2021.623087. PMID: 34262557.

Read more →
Source

Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome

Eligible participants were randomized 1:1:1:1 to placebo, 1000, 5000 or 10 000 international units (IU) of oral vitamin D3 daily within each study centre (n = 23) and followed for up to 48 weeks.

Publication details

[7] Butzkueven H et al. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain : a journal of neurology. 2024;147(4):1206-1215. DOI: 10.1093/brain/awad409. PMID: 38085047.

Read more →
Source

Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial

Published in Arthritis & rheumatology (Hoboken, N.J.) (2024).

Publication details

[9] Costenbader KH et al. Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.). 2024;76(6):973-983. DOI: 10.1002/art.42811. PMID: 38272846.

Read more →